Mobiquity Technologies Launches CMOne – A Fully Agentic AI Marketing Platform for Unified Brand Engagement
Short for 'CMO + One,' CMOne is designed to operate as an intelligent command center for brands, performance marketers, and agencies. It enables users to manage, scale, and optimize every component of their marketing strategy within a single platform.
'Marketing has become a fragmented, tool-heavy experience that slows down performance and drowns teams in complexity,' said Dean Julia, CEO of Mobiquity Technologies. 'With CMOne, we're introducing a new operating system for marketing—one that thinks, acts, and grows like your best team member, but works 24/7. It's not just AI-powered; it's fully agentic.'
Key Features of CMOne:
AI Content Creation – Generates branded assets, short-form videos, carousels, and copy for email, SMS, and messaging platforms.
Omnichannel Publishing Engine – Schedules and posts content across Instagram, LinkedIn, TikTok, WhatsApp, Discord, Email, Telegram, and more.
Ad Intelligence Engine – Launches and optimizes ads across platforms like Hulu, Spotify, Reddit, TikTok, and Taboola in real time.
Unified Performance Dashboard – Tracks engagement, sentiment, ROAS, and brand consistency while autonomously adjusting campaign strategy.
Built on Mobiquity's proven AdTech infrastructure and leveraging the programmatic expertise of its subsidiaries, CMOne seamlessly combines:
Organic and paid content strategies
Messaging and community management
Creative development and real-time media buying
Performance analytics and continuous optimization
From direct-to-consumer startups to global enterprises, CMOne allows teams to move from ideation to execution—without switching tools, writing prompts, or losing control over brand messaging.
About Mobiquity Technologies
Mobiquity Technologies, Inc. (OTCQB: MOBQ) is an advertising and data intelligence company that utilizes AI to deliver programmatic media, audience targeting, and real-time behavioral insights across mobile, CTV, digital out-of-home, social media and in-venue screens. Through its subsidiaries, Advangelists, Mobiquity Networks and AdHere and several strategic partnerships, Mobiquity powers innovative campaigns—bridging digital and physical environments to drive engagement through contextually relevant, data-driven advertising.
Safe Harbor Statement
This press release contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. In some cases, forward-looking statements can be identified by words or phrases such as "may," "will," "expect," "anticipate," "target," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to" or other similar expressions. Further information regarding these and other risks, uncertainties, or factors is included in the Company's filings with the SEC. All information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information except as required under applicable law.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
6 minutes ago
- Globe and Mail
J&J Expects Better Top-Line Growth in 2H: Can It Achieve the Goal?
Johnson & Johnson JNJ announced strong second-quarter results earlier this month. The drug and medical device giant beat estimates for both earnings and sales. Despite the loss of exclusivity ('LOE') of its blockbuster drug, Stelara, its Innovative Medicine unit once again outperformed expectations, with sales of all key drugs Darzalex, Erleada and Tremfya beating estimates. The new drugs also contributed significantly to sales. Importantly, its MedTech sales improved from first-quarter levels, driven by strong momentum in Cardiovascular, Surgery and Vision segments despite continued headwinds in China. But what caught investor attention is the fact that J&J raised its sales expectations for 2025 by around $2.0 billion at the mid-point to reflect a strong operational performance in the first half, coupled with currency tailwinds. The sales guidance was raised from a range of $91.0 billion-$91.8 billion to $93.2 billion-$93.4 billion. The sales range indicates growth in the range of 5.1%-5.6% versus the prior expectation of 2.6%-3.6%. The adjusted earnings per share guidance was raised from a range of $10.50-$10.70 to $10.80-$10.90, driven by top-line strength, the favorable impact of foreign currency and lowered tariff impact. J&J halved its expectations for tariff-related costs this year from $400 million to $200 million. J&J expects operational sales growth in both the Innovative Medicine and MedTech segments to be higher in the second half than in the first. Newly launched products should drive better growth in the Innovative Medicine segment in the second half despite the impact of Stelara LOE and Medicare Part D redesign. The growth is expected to be driven by its key products, such as Darzalex, Tremfya, Spravato and Erleada as well as new drugs like Carvykti, Tecvayli and Talvey and new indications, including Tremfya in inflammatory bowel disease indications and Rybrevant in non-small cell lung cancer. In the MedTech segment, the increased adoption of newly launched products in Cardiovascular, Surgery and Vision is likely to drive growth. However, China will continue to be a headwind in 2025. Sales are expected to be higher in the second half than the first half as the business moves past tougher first-half comps and new products gain momentum throughout 2025. We believe that J&J should be able to maintain the strong momentum of the first half in the second half. In fact, J&J expects growth to accelerate from 2026. ABBV & BMY Also Raise Guidance Other drugmakers that also raised their financial outlook for the year, along with their second-quarter results, are AbbVie ABBV and Bristol-Myers BMY. ABBV raised its full-year 2025 EPS guidance to $11.88-$12.08, up from its prior $11.67-$11.87 range.' Bristol-Myers raised its annual revenue guidance to $46.5-$47.5 billion from $45.8-$46.8 billion. BMY, however, cut its EPS outlook due to IPRD charges related to its recent deal with BioNTech BNTX for the global co-development and co-commercialization of BNTX's investigational bispecific antibody BNT327 across numerous solid tumor types. JNJ's Price Performance, Valuation and Estimates J&J's shares have outperformed the industry year to date. The stock has risen 17.6% in the year-to-date period against a 3.3% decrease of the industry. Image Source: Zacks Investment Research From a valuation standpoint, J&J is slightly expensive. Going by the price/earnings ratio, the company's shares currently trade at 15.0 forward earnings, slightly higher than 14.29 for the industry. The stock is, however, trading below its five-year mean of 15.68. Image Source: Zacks Investment Research The Zacks Consensus Estimate for 2025 earnings has risen from $10.62 per share to $10.86 over the past 30 days, while that for 2026 has risen from $11.0 to $11.36 over the same timeframe. Image Source: Zacks Investment Research J&J has a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Zacks Names #1 Semiconductor Stock This under-the-radar company specializes in semiconductor products that titans like NVIDIA don't build. It's uniquely positioned to take advantage of the next growth stage of this market. And it's just beginning to enter the spotlight, which is exactly where you want to be. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $971 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Bristol Myers Squibb Company (BMY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report BioNTech SE Sponsored ADR (BNTX): Free Stock Analysis Report
Globe and Mail
6 minutes ago
- Globe and Mail
Stock Market News for Aug 4, 2025
U.S. stocks tumbled on Friday, with the S&P 500 recording its biggest daily percentage decline in over two months, as hefty tariffs slapped on dozens of countries by President Donald Trump and an unexpectedly weak jobs report raised concerns over a weakening economy. All three major indexes ended in negative territory. How Did The Benchmarks Perform? The Dow Jones Industrial Average (DJI) slid 1,2% or 542.40 points, to finish at 43,588.58 points. The S&P 500 declined 1.6%, or 101.38 points, to end at 6,238.01 points, posting its worst day since May 21. Consumer discretionary, tech and financial stocks were the worst performers. The Consumer Discretionary Select Sector SPDR (XLY) declined 2.4%. The Financials Select Sector SPDR (XLF) and the Technology Select Sector SPDR (XLK) slid 2.2 and 1.9%, respectively. Eight of the 11 sectors of the benchmark index ended in negative territory. The tech-heavy Nasdaq fell 2.2%, or 472.32 points, to close at 20,650.13 points, recording its biggest single-day decline since April 21. The fear gauge CBOE Volatility Index (VIX) was up 21.89% to 20.38. Decliners outnumbered advancers on the NYSE by a 2.17-to-1 ratio. On the Nasdaq, a 2.69-to-1 ratio favored declining issues. A total of 19.51 billion shares were traded on Friday, higher than the last 20-session average of 18.44 billion. Trump's New Tariffs, Weak Jobs Data Dent Investors' Confidence Trump signed an executive order hours before the Aug. 1 tariff deadline and slapped hefty duties on several trading partners of the United States, including Brazil, Canada, India and Taiwan, as these countries scrambled to work out fairer trade deals. Investors grew concerned once again as they believe that hefty tariffs could weigh on an already weakening economy and push inflation further up. Investors' confidence took a further hit after fresh data showed that jobs growth unexpectedly slowed in July, while June's numbers were downwardly revised, suggesting that the labor market is likely shrinking. Bank stocks took a hit on concerns that a slowing economy could impact loan growth. Shares of JPMorgan Chase & Co. ( JPM ) fell 2.3%, while Bank of America Corporation ( BAC ) and Wells Fargo & Company ( WFC ) declined 3.4% and 3.5%, respectively. This, however, raised hopes that the Federal Reserve will cut interest rates in its September policy meeting. The weak jobs data raised market expectations of a 25-basis-point rate cut in September to 86.5%, according to the CME's FedWatch Tool, up from 37.7% in Thursday's session. Amazon Weighs on Broader Market E-commerce giant Inc. ( AMZN ) was the biggest drag on all three major indexes. Amazon topped both earnings and revenue estimates. The company reported second-quarter earnings of $1.68 per share, beating the Zacks Consensus Estimate of $1.33 per share. The e-commerce giant posted revenues of $167.7 billion for the quarter, surpassing the Zacks Consensus Estimate by 3.32% However, the company's shares declined 8.3% after it failed to meet the expectations for its Amazon Web Services. Amazon Web Services revenues grew 18% in the second quarter, but its growth rate lagged Microsoft Corporation's ( MSFT ) Azure's 39% and Alphabet, Inc.'s ( GOOGL ) Google Cloud's 32% growth rate. Amazon has a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Economic Data The Labor Department reported on Friday that nonfarm payrolls increased by just 73,000 in July, sharply lower than analysts' expectations of a rise of 100,000. June's jobs growth was downwardly revised to just 14,000, from 147,000, while May's numbers totaled just 19,000 after being cut down from the initially reported 125,000. The unemployment rate jumped to 4.2% in July as household employment declined. Weekly Roundup All three indexes ended lower for the week. The Dow lost 2.9% for the week. The S&P 500 was down 2.4% for the week, while the Nasdaq lost 2.2%. Zacks Names #1 Semiconductor Stock This under-the-radar company specializes in semiconductor products that titans like NVIDIA don't build. It's uniquely positioned to take advantage of the next growth stage of this market. And it's just beginning to enter the spotlight, which is exactly where you want to be. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $971 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Inc. (AMZN): Free Stock Analysis Report Bank of America Corporation (BAC): Free Stock Analysis Report Wells Fargo & Company (WFC): Free Stock Analysis Report JPMorgan Chase & Co. (JPM): Free Stock Analysis Report Alphabet Inc. (GOOGL): Free Stock Analysis Report
Globe and Mail
10 minutes ago
- Globe and Mail
HNI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of HNI Corporation Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of HNI Corporation (NYSE: HNI) and Steelcase Inc. is fair to HNI shareholders. Upon closing of the proposed transaction, HNI shareholders will own approximately 64% of the combined company. Halper Sadeh encourages HNI shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@ or zhalper@ The investigation concerns whether HNI and its board violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for HNI shareholders; and (2) disclose all material information necessary for HNI shareholders to adequately assess and value the merger consideration. On behalf of HNI shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits. We would handle the action on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors. Attorney Advertising. Prior results do not guarantee a similar outcome.
